

Jan Gray Joins Resverlogix Board of Directors

Calgary, AB, July 25, 2008 – Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) is pleased to announce effective immediately Jan Gray, CA has joined the Company’s Board of Directors. On the subject of her appointment Jan Gray said, “Working with Resverlogix represents an exciting opportunity for me. The Company has done a wonderful job moving forward its lead drug into clinical trials. I expect the next foreseeable future to be both busy and very exciting. I am delighted to be joining the Board of Resverlogix.”

“Jan’s background as a chartered accountant adds a new skill set to the current Board of Directors, which is fundamental to the operation of the group in today’s complex financial reporting environment. We are very pleased that she has agreed to join Resverlogix’s Board,” stated Donald McCaffrey, President and CEO of Resverlogix. “Jan brings to us a wealth of strategic and organizational excellence. In addition to her duties as a Board member Jan will provide sound counsel to our audit committee.”

Jan Gray, CA is a practicing chartered accountant who specializes in advising high net worth individuals with complex financial, investment and taxation issues. She is also Executive Vice-President and Treasurer of Cartwright Canada Inc., a legal publishing company and Controller of Felesky Flynn LLP, a regional Alberta law firm. Ms. Gray’s prior experience includes being a former Vice President and Controller of GE Capital Canada and previous to this she worked for Ernst & Young where she was a Manager in the National Accounting Group providing quality assurance on large public practice engagements.

Ms. Gray currently serves on the board of directors of GE Money Trust Company, a unit of General Electric Company and the Auxilium Foundation where she administers the multi-million dollar charitable fund. In addition Jan is a regular volunteer with Inn From the Cold, Calgary’s only shelter for homeless families which allows the family to remain together.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas™ program is the Company’s primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as acute coronary syndrome, diabetes, Alzheimer’s disease and other vascular disorders. The Company’s secondary focus is TGF-Beta Shield™, a program that aims to address burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

For further information please contact:

Theresa Kennedy
VP, Corporate Communications
Resverlogix Corp.
Phone: 604-538-7072
Email: Theresa@resverlogix.com

Don McCaffrey
President & CEO
Resverlogix Corp.
Phone: 403-254-9252
Email: Don@resverlogix.com

Website: www.resverlogix.com